402 related articles for article (PubMed ID: 32066648)
1. Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration.
Maximova N; Maestro A; Zanon D; Marcuzzi A
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32066648
[TBL] [Abstract][Full Text] [Related]
2. DRESS syndrome due to vemurafenib treatment: switching BRAF inhibitor to solve a big problem.
Ros J; Muñoz-Couselo E
BMJ Case Rep; 2018 Sep; 2018():. PubMed ID: 30275021
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
Naqash AR; File DM; Ziemer CM; Whang YE; Landman P; Googe PB; Collichio FA
J Immunother Cancer; 2019 Jan; 7(1):4. PubMed ID: 30621779
[TBL] [Abstract][Full Text] [Related]
4. A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
Franken MG; Leeneman B; Gheorghe M; Uyl-de Groot CA; Haanen JBAG; van Baal PHM
Eur J Cancer; 2019 Dec; 123():58-71. PubMed ID: 31670077
[TBL] [Abstract][Full Text] [Related]
5. Early-Onset Vemurafenib-Induced DRESS Syndrome.
Munch M; Peuvrel L; Brocard A; Saint Jean M; Khammari A; Dreno B; Quereux G
Dermatology; 2016; 232(1):126-8. PubMed ID: 26418832
[TBL] [Abstract][Full Text] [Related]
6. Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy.
Johnson DB; Wallender EK; Cohen DN; Likhari SS; Zwerner JP; Powers JG; Shinn L; Kelley MC; Joseph RW; Sosman JA
Cancer Immunol Res; 2013 Dec; 1(6):373-7. PubMed ID: 24490176
[TBL] [Abstract][Full Text] [Related]
7. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients.
Daud A; Gill J; Kamra S; Chen L; Ahuja A
J Hematol Oncol; 2017 Jan; 10(1):3. PubMed ID: 28052762
[TBL] [Abstract][Full Text] [Related]
8. Two cases of successful treatment for severe skin rash induced by vemurafenib following nivolumab therapy without cessation of vemurafenib.
Tsuboi S; Yoshino K; Yamaguchi K; Imafuku K; Ohara K
J Dermatol; 2017 May; 44(5):607-608. PubMed ID: 27334634
[No Abstract] [Full Text] [Related]
9. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials.
Hopkins AM; Rathod AD; Rowland A; Kichenadasse G; Sorich MJ
BMC Cancer; 2020 Feb; 20(1):157. PubMed ID: 32103736
[TBL] [Abstract][Full Text] [Related]
11. Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases.
Ingen-Housz-Oro S; Milpied B; Bensaid B; Elshot Y; Brüggen MC; Starace M; Kaffenberger BH; Carrera C; Pham-Ledard A; Freites-Martinez A; Sanchez-Pena P; Lebrun-Vignes B; French LE; Sibaud V
Melanoma Res; 2023 Apr; 33(2):155-158. PubMed ID: 36749114
[TBL] [Abstract][Full Text] [Related]
12. Paediatric case series of drug reaction with eosinophilia and systemic symptoms (DRESS): 12-year experience at a single referral centre in Hong Kong and the first reported use of infliximab.
Chua GT; Rosa Duque JS; Chong PCY; Lee PPW; Lau YL; Ho MHK
Eur Ann Allergy Clin Immunol; 2018 Nov; 50(6):273-276. PubMed ID: 29384118
[TBL] [Abstract][Full Text] [Related]
13. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF
Gutzmer R; Stroyakovskiy D; Gogas H; Robert C; Lewis K; Protsenko S; Pereira RP; Eigentler T; Rutkowski P; Demidov L; Manikhas GM; Yan Y; Huang KC; Uyei A; McNally V; McArthur GA; Ascierto PA
Lancet; 2020 Jun; 395(10240):1835-1844. PubMed ID: 32534646
[TBL] [Abstract][Full Text] [Related]
14. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
[TBL] [Abstract][Full Text] [Related]
15. Drug rash with eosinophilia and systemic symptoms syndrome masquerading as a lymphoproliferative disorder in a young adult on immunosuppressive therapy for rheumatoid arthritis: a case report.
Hyser E
J Med Case Rep; 2022 Sep; 16(1):336. PubMed ID: 36059007
[TBL] [Abstract][Full Text] [Related]
16. Severe skin eruption with features of drug reaction with eosinophilia and systemic symptoms (DRESS) during vemurafenib treatment of melanoma.
Kohlmann J; Reschke R; Mockenhaupt M; Ziemer M
J Eur Acad Dermatol Venereol; 2022 Mar; 36(3):e242-e244. PubMed ID: 34704628
[No Abstract] [Full Text] [Related]
17. Vemurafenib-induced DRESS/DIHS resulting in spontaneous melanoma regression: an immunological reaction shedding new light on melanoma treatment?
Olteanu C; Scope A; Steinberg-Silman Y; Ziv M; Shear NH; Dodiuk-Gad RP; Markel G
Int J Dermatol; 2020 May; 59(5):e139-e141. PubMed ID: 32212333
[No Abstract] [Full Text] [Related]
18. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
19. Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.
Peters S; Bouchaab H; Zimmerman S; Bucher M; Gaide O; Letovanec I; Homicsko K; Michielin O
Melanoma Res; 2014 Oct; 24(5):496-500. PubMed ID: 25185693
[TBL] [Abstract][Full Text] [Related]
20. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
